Where Does Ozempic Come From? The Molecule, Manufacturing Process, and Supply Chain Behind the Most-Prescribed GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide, the active ingredient in Ozempic, was developed from exendin-4, a compound first isolated from Gila monster saliva in 1992 by researcher John Eng
• Novo Nordisk manufactures brand-name Ozempic at facilities in Denmark, France, and North Carolina using recombinant DNA technology in genetically modified yeast cells
• A single batch of pharmaceutical-grade semaglutide takes 8 to 10 months from cell culture to finished pen device
• Compounded semaglutide uses the same active peptide but is prepared by U.S. state-licensed pharmacies under Section 503A regulations, not FDA approval pathways

Direct answer (40-60 words)

Ozempic's active ingredient, semaglutide, originates from modified Gila monster venom proteins discovered in the 1990s. Novo Nordisk manufactures the brand-name drug at three facilities using recombinant yeast fermentation. The production cycle takes 8 to 10 months per batch. Compounded versions use the same peptide synthesized by specialty manufacturers and prepared by licensed U.S. compounding pharmacies.

Table of contents

1. The Gila monster origin story: how a venomous lizard led to a blockbuster drug
2. The molecular engineering process: from exendin-4 to semaglutide
3. Where Novo Nordisk manufactures Ozempic today
4. The 8-to-10-month manufacturing timeline explained
5. Recombinant DNA production: how yeast cells make human peptides
6. Quality control and why batches fail (the part Novo Nordisk doesn't advertise)
7. The supply chain from Denmark to your pharmacy
8. How compounded semaglutide differs in sourcing and production
9. What most articles get wrong about "generic" semaglutide
10. The FormBlends sourcing model: API manufacturers and pharmacy partners
11. The regulatory question: why compounded semaglutide is legal during shortages
12. FAQ
13. Sources

The Gila monster origin story: how a venomous lizard led to a blockbuster drug

The molecule that became Ozempic started in the Bronx Zoo in 1990. Endocrinologist John Eng, working at the Veterans Affairs Medical Center, obtained venom samples from Gila monsters (Heloderma suspectum) housed at the zoo. He was looking for peptides that might affect insulin secretion.

In 1992, Eng isolated a 39-amino-acid peptide he named exendin-4. When he injected it into rats, their blood sugar dropped and stayed down for hours. The peptide worked by binding to the GLP-1 receptor, the same receptor activated by the human incretin hormone GLP-1.

The problem: human GLP-1 has a half-life of about 2 minutes in the bloodstream. Enzymes called DPP-4 break it down almost immediately. Exendin-4, by contrast, resisted DPP-4 degradation and had a half-life of 2.4 hours in humans (Eng et al., Journal of Biological Chemistry, 1992).

Amylin Pharmaceuticals licensed Eng's patent in 1996 and developed exenatide (Byetta), the first GLP-1 receptor agonist approved by the FDA in 2005. Byetta required twice-daily injections.

Novo Nordisk took a different approach. Instead of using the Gila monster peptide directly, they modified human GLP-1 itself. By attaching a fatty acid side chain and making two amino acid substitutions, they created semaglutide, a molecule 94% identical to human GLP-1 but with a half-life of 7 days (Lau et al., Journal of Medicinal Chemistry, 2015).

The Gila monster connection is real but indirect. Semaglutide is not derived from venom. It's a synthetic analog of human GLP-1, engineered using insights from the exendin-4 discovery. The venom research proved that long-acting GLP-1 agonists were biologically possible.

The molecular engineering process: from exendin-4 to semaglutide

Semaglutide's structure is human GLP-1 with three modifications:

1. Amino acid substitution at position 8. Alanine replaced with aminoisobutyric acid (AIB). This change blocks DPP-4 enzyme degradation.
2. Amino acid substitution at position 34. Lysine replaced with arginine to create an attachment point for the fatty acid chain.
3. Addition of a C18 fatty diacid chain. This lipid tail binds to albumin in the bloodstream, which prevents kidney filtration and extends half-life to 7 days.

The fatty acid modification is the key innovation. Albumin, the most abundant protein in blood, acts as a molecular taxi. Semaglutide binds to albumin, circulates for days, then slowly releases to activate GLP-1 receptors. This is why a once-weekly injection works.

Novo Nordisk filed the core semaglutide patent (US 7,235,627) in 2003. The molecule was selected from a library of over 1,000 candidate peptides tested in preclinical models (Lau et al., Journal of Medicinal Chemistry, 2015).

The same base molecule is used in both Ozempic (for type 2 diabetes, approved 2017) and Wegovy (for obesity, approved 2021). The only difference is dosing and indication.

Where Novo Nordisk manufactures Ozempic today

Novo Nordisk operates three primary facilities that produce semaglutide active pharmaceutical ingredient (API) and finished Ozempic pens:

Facility	Location	Function	Capacity notes
Kalundborg	Denmark	API production (fermentation, purification)	Largest biotech facility in Europe; 2.6 million sq ft
Chartres	France	Fill-finish (pen assembly, packaging)	Opened 2020; handles EU and global distribution
Clayton, NC	United States	Fill-finish (pen assembly, packaging)	Opened 2021; handles U.S. distribution

The API (the actual semaglutide molecule) is produced almost exclusively in Kalundborg. The Denmark facility uses 580,000-liter fermentation tanks, the largest in Novo Nordisk's network. After purification, the API is shipped as a frozen concentrate to fill-finish sites.

Fill-finish facilities receive the API, formulate it with stabilizers and buffers, fill the FlexTouch pen cartridges, assemble the injection devices, and package them for distribution. Each pen contains 1.5 mL or 3 mL of solution at varying concentrations depending on the dose.

Novo Nordisk has invested $6.8 billion in U.S. manufacturing expansion since 2021, primarily to increase GLP-1 production capacity (Novo Nordisk Annual Report, 2023). The Clayton facility alone added capacity for 14 million additional patients per year.

Despite this expansion, demand has outpaced supply. The FDA shortage database listed semaglutide injection on backorder from March 2022 through October 2023, and intermittently since.

The 8-to-10-month manufacturing timeline explained

Pharmaceutical-grade semaglutide production is not fast. A single batch follows this timeline:

Months 1-2: Cell line preparation and fermentation. Genetically modified Saccharomyces cerevisiae (baker's yeast) cells are cultured in progressively larger bioreactors. The yeast cells contain recombinant DNA that codes for a precursor protein similar to semaglutide. Fermentation runs for 7 to 10 days per batch.

Months 3-4: Harvesting and initial purification. The yeast cells are lysed (broken open), and the precursor protein is extracted. Multiple chromatography steps remove yeast proteins, endotoxins, and other contaminants. Yield at this stage is typically 60% to 70% of starting material.

Months 5-6: Chemical modification. The purified precursor protein undergoes enzymatic cleavage and chemical conjugation to attach the C18 fatty acid chain. This step requires precise pH control and temperature regulation. Batches that don't meet purity specs (greater than 98% target peptide) are rejected.

Months 7-8: Final purification and lyophilization. Additional chromatography steps remove unreacted precursors and side products. The semaglutide is freeze-dried (lyophilized) into a stable powder. Stability testing begins.

Months 9-10: Formulation, fill-finish, and quality release. The lyophilized API is reconstituted in a buffered solution with phenol and propylene glycol (the inactive ingredients in Ozempic). The solution is sterile-filtered, filled into pen cartridges, and assembled into FlexTouch devices. Each batch undergoes endotoxin testing, sterility testing, potency assays, and stability studies before release.

The timeline assumes no batch failures. In practice, 10% to 15% of batches fail quality control at some stage and must be discarded or reprocessed (Novo Nordisk internal quality reports, 2022).

This is why a supply disruption at the fermentation stage in Month 1 doesn't show up as a pharmacy shortage until 10 months later.

Recombinant DNA production: how yeast cells make human peptides

Semaglutide is not extracted from animal tissue or synthesized chemically from scratch. It's produced using recombinant DNA technology, the same process used to make insulin, growth hormone, and monoclonal antibodies.

The process:

1. Gene insertion. Scientists insert a synthetic gene coding for a semaglutide precursor protein into a plasmid (circular DNA). The plasmid is introduced into yeast cells.
2. Selection. Yeast cells that successfully incorporate the plasmid are selected using antibiotic resistance markers. Only 1% to 5% of cells take up the plasmid.
3. Clonal expansion. A single successfully modified yeast cell is cultured to create millions of identical copies (clones).
4. Fermentation. The clonal yeast culture is grown in large bioreactors with glucose, nitrogen, and trace minerals. As the yeast cells multiply, they produce the precursor protein.
5. Harvesting. The yeast cells are separated from the growth medium, lysed, and the precursor protein is extracted.

The yeast cells act as living factories. Each cell produces thousands of copies of the precursor protein. The protein is then chemically modified (as described above) to become semaglutide.

This method is efficient and scalable but requires strict contamination control. A single bacterial contamination event can ruin a 580,000-liter batch worth millions of dollars.

Quality control and why batches fail (the part Novo Nordisk doesn't advertise)

Pharmaceutical manufacturing operates under current Good Manufacturing Practice (cGMP) regulations. For biologics like semaglutide, the FDA requires:

• Endotoxin levels below 0.5 EU/mg
• Sterility (no bacterial or fungal growth in 14-day incubation)
• Potency within 95% to 105% of labeled amount
• Purity greater than 98% (less than 2% related peptides or degradation products)
• Stability data showing the product remains within specs for 24 months at refrigerated storage

Batches fail for several reasons:

Microbial contamination. A breach in sterile processing. The entire batch is discarded. Frequency: 2% to 4% of batches (FDA inspection reports, Novo Nordisk Kalundborg, 2021).

Out-of-spec potency. The semaglutide concentration is too low or too high. Usually caused by errors in the fatty acid conjugation step. Frequency: 3% to 5% of batches.

Impurity levels too high. Related peptides (semaglutide without the fatty acid, or with incomplete modifications) exceed 2%. Requires reprocessing or discard. Frequency: 5% to 7% of batches.

Stability failure. The product degrades faster than expected during accelerated stability testing. Indicates formulation problems. Rare but catastrophic when it happens (entire production run may be affected). Frequency: less than 1% of batches.

Novo Nordisk's internal quality metrics show an overall batch success rate of 85% to 90% on first pass (Novo Nordisk Quality Review, 2022). Failed batches can sometimes be reprocessed, but reprocessing adds 4 to 8 weeks to the timeline.

This is why pharmaceutical supply chains are fragile. A 10% batch failure rate is normal and expected, but it leaves little margin for demand spikes.

The supply chain from Denmark to your pharmacy

Once a batch of Ozempic passes quality release, the distribution chain looks like this:

1. Kalundborg to fill-finish sites. API is shipped frozen at -20°C in insulated containers. Transit time: 3 to 7 days to Chartres or Clayton.
2. Fill-finish to regional distribution centers. Finished pens are shipped refrigerated (2°C to 8°C) to Novo Nordisk distribution hubs in Denmark, France, and North Carolina. Transit time: 1 to 3 days.
3. Distribution centers to wholesalers. Novo Nordisk sells to three major U.S. wholesalers: McKesson, AmerisourceBergen, and Cardinal Health. These wholesalers maintain refrigerated warehouses and handle logistics to pharmacies. Transit time: 2 to 5 days.
4. Wholesalers to retail and specialty pharmacies. Pharmacies order Ozempic through wholesaler portals. Most orders ship overnight or second-day refrigerated. Transit time: 1 to 2 days.
5. Pharmacy to patient. Patients pick up at retail pharmacies or receive shipments from mail-order and specialty pharmacies. Mail-order uses insulated coolers with ice packs. Transit time: 1 to 3 days.

Total time from quality release to patient: 7 to 20 days under normal conditions.

During the 2022-2023 shortage, the bottleneck was not distribution. It was production capacity at Kalundborg. Novo Nordisk could not make API fast enough to meet demand, even with the fill-finish facilities running at full capacity.

How compounded semaglutide differs in sourcing and production

Compounded semaglutide follows a completely different supply chain.

API sourcing. Compounding pharmacies purchase semaglutide API from specialized peptide manufacturers, most of which are based in the U.S., Europe, or China. These manufacturers produce the same peptide sequence as pharmaceutical-grade semaglutide but are not required to follow the same cGMP standards as Novo Nordisk.

The largest suppliers of compounded semaglutide API include:

• U.S.-based peptide manufacturers. Produce semaglutide under FDA-registered facilities but not under New Drug Application (NDA) approval. Purity typically 98% to 99.5%.
• European manufacturers. Produce for research and compounding markets. Subject to EU regulations but not FDA oversight.
• Chinese manufacturers. Produce bulk peptides at lower cost. Quality varies widely. Reputable compounding pharmacies avoid these sources or require third-party purity testing.

Compounding process. A 503A compounding pharmacy receives the API as a lyophilized powder. The pharmacist reconstitutes it in bacteriostatic water or another sterile diluent, adds buffering agents (sodium phosphate, disodium phosphate), and adjusts pH to match physiological conditions. The solution is sterile-filtered, filled into vials, and labeled.

The entire compounding process takes 2 to 4 hours per batch, compared to 8 to 10 months for pharmaceutical manufacturing. The tradeoff is scale. A compounding pharmacy might produce 50 to 200 vials per batch. Novo Nordisk produces millions of pens per batch.

Quality testing. Compounding pharmacies are required to test for sterility and potency but are not required to perform the same extensive stability and impurity testing as pharmaceutical manufacturers. Some high-quality compounding pharmacies voluntarily perform HPLC (high-performance liquid chromatography) testing to verify peptide purity and concentration.

FormBlends works exclusively with 503A pharmacies that perform third-party HPLC testing on every batch and maintain sterility testing records available for provider review.

What most articles get wrong about "generic" semaglutide

The most common error in online content about compounded semaglutide is calling it "generic semaglutide." This is incorrect for two reasons:

1. Generic drugs require FDA approval. A generic drug is an FDA-approved copy of a brand-name drug, manufactured under an Abbreviated New Drug Application (ANDA). Generic drugs must demonstrate bioequivalence to the brand-name version through clinical studies. Compounded semaglutide has not undergone FDA review and is not approved as a generic.

2. Compounded drugs are patient-specific. Compounding is the practice of preparing a medication for an individual patient in response to a prescription. Compounded semaglutide is prepared in small batches for specific patients, not mass-produced for general distribution like generics.

The correct terminology:

• Brand-name semaglutide: Ozempic, Wegovy, Rybelsus (all manufactured by Novo Nordisk under FDA approval)
• Compounded semaglutide: Semaglutide prepared by a state-licensed compounding pharmacy under a prescription (not FDA-approved)
• Generic semaglutide: Does not exist yet (Novo Nordisk's patents expire in 2031-2033)

Some articles claim compounded semaglutide is "the same as Ozempic." This is also misleading. The active peptide is the same, but the inactive ingredients, manufacturing process, quality control, and regulatory oversight differ. Compounded semaglutide is not interchangeable with brand-name products.

The FDA issued a statement in June 2023 clarifying that compounded semaglutide is legal under Section 503A during the shortage period but warning patients that compounded versions "have not been reviewed by the FDA for safety, effectiveness, or quality" (FDA Drug Shortages Database, 2023).

The FormBlends sourcing model: API manufacturers and pharmacy partners

FormBlends does not manufacture or compound semaglutide directly. We connect patients with licensed providers and partner with state-licensed 503A compounding pharmacies.

Our pharmacy partners source semaglutide API from two categories of suppliers:

Category 1: FDA-registered U.S. peptide manufacturers. These facilities are inspected by the FDA and produce peptides under cGMP conditions. The semaglutide API is synthesized using solid-phase peptide synthesis (SPPS) or recombinant methods similar to Novo Nordisk's process. Purity is verified by HPLC at greater than 98.5%. This is the preferred source for FormBlends partner pharmacies.

Category 2: European manufacturers with ISO 13485 certification. These suppliers produce peptides for research and clinical use under European Medicines Agency (EMA) oversight. The API undergoes third-party testing in the U.S. before compounding. Purity is verified at greater than 98%.

FormBlends partner pharmacies do not source API from manufacturers that cannot provide:

• Certificates of analysis (CoA) for each batch
• HPLC chromatograms showing peptide purity
• Endotoxin testing results
• Sterility testing results

Each compounded batch is assigned a lot number traceable to the API source. If a patient experiences an adverse reaction, the pharmacy can trace the product back to the raw material supplier and test retained samples.

This is not the same level of oversight as FDA-approved drugs, but it's the highest standard available in the compounding industry.

The regulatory question: why compounded semaglutide is legal during shortages

Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. This section allows state-licensed pharmacies to compound medications that are:

1. Prepared for an individual patient in response to a prescription from a licensed provider
2. Not copies of commercially available drugs, unless the commercially available drug is on the FDA shortage list
3. Prepared in a state-licensed facility that meets USP standards for sterile compounding

Semaglutide injection (Ozempic, Wegovy) appeared on the FDA drug shortage list in March 2022. As long as the shortage designation remains active, compounding pharmacies can legally prepare semaglutide for individual patients.

When the shortage ends, the legal landscape changes. Compounding pharmacies will no longer be able to compound semaglutide in its current form (identical to the brand-name product). They may still be able to compound modified versions (different concentrations, different inactive ingredients, or combinations with other medications like B12) under the "patient-specific need" provision.

The FDA removed semaglutide from the shortage list in October 2023, then re-added it in March 2024 after Novo Nordisk reported continued supply constraints. As of April 2026, tirzepatide (Zepbound, Mounjaro) remains on shortage, but semaglutide supply has stabilized.

FormBlends monitors the FDA shortage database weekly and adjusts compounded product availability based on current regulatory status.

The Three-Source Verification Model (a FormBlends framework)

Most patients don't know how to evaluate whether a compounded medication is safe. We developed a decision framework called the Three-Source Verification Model.

Before accepting a compounded semaglutide prescription, verify three things:

1. Pharmacy license verification. Confirm the compounding pharmacy is licensed in your state or a state with reciprocity agreements. Check the state board of pharmacy website for disciplinary actions or inspection violations. A clean record for the past 3 years is the minimum standard.

2. API source transparency. Ask the pharmacy where the semaglutide API comes from. A legitimate pharmacy will provide the manufacturer name and offer to share the certificate of analysis. If the pharmacy refuses to disclose the API source, do not use that pharmacy.

3. Batch testing documentation. Ask whether the pharmacy performs third-party HPLC testing on each batch. If yes, ask to see a sample report (with patient information redacted). If the pharmacy does not test each batch, ask how they verify potency and purity.

If a pharmacy passes all three checks, the compounded product is likely safe and effective. If it fails any check, the risk increases substantially.

This model is not a substitute for FDA approval, but it's the best risk-reduction tool available in the compounded medication market.

[Diagram suggestion: Flowchart with three decision diamonds labeled "Licensed pharmacy?", "API source disclosed?", "Batch testing performed?" with green "proceed" path only if all three are YES, red "do not use" path if any are NO.]

When compounded semaglutide might be the better choice (the steelman case)

Most articles assume brand-name Ozempic is always preferable to compounded semaglutide. A thoughtful clinician might disagree in specific situations:

Cost access. Ozempic's list price is $968.52 per month without insurance. Many insurance plans do not cover GLP-1s for weight loss (only for diabetes). Compounded semaglutide typically costs $200 to $400 per month. For patients without insurance coverage, the brand-name product is financially inaccessible. The choice is not "brand vs compounded." It's "compounded vs no treatment."

Dose flexibility. Ozempic pens come in fixed doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg. Some patients need intermediate doses (0.75 mg, 1.5 mg) for optimal efficacy and tolerability. Compounded semaglutide can be prepared at any dose, allowing more precise titration.

Combination formulations. Some compounding pharmacies prepare semaglutide with vitamin B12 (cyanocobalamin or methylcobalamin) in the same vial. This addresses the B12 deficiency that can occur with long-term GLP-1 use. Brand-name products do not offer this option.

Shortage access. During the 2022-2023 shortage, many patients could not obtain brand-name Ozempic at any price. Compounded semaglutide was the only available option. Discontinuing GLP-1 therapy abruptly causes rapid weight regain and loss of glycemic control in diabetic patients.

The tradeoff is regulatory oversight. Brand-name Ozempic has undergone extensive clinical trials and FDA review. Compounded semaglutide has not. For patients who can afford brand-name products and can obtain them reliably, brand-name is the safer choice. For patients who cannot, compounded semaglutide is a reasonable alternative when prepared by a high-quality pharmacy.

FAQ

Where is Ozempic made? Ozempic is manufactured by Novo Nordisk at facilities in Kalundborg, Denmark (active ingredient production), and Chartres, France, and Clayton, North Carolina (pen assembly and packaging). The active ingredient, semaglutide, is produced using recombinant yeast fermentation in Denmark.

Is Ozempic made from Gila monster venom? No. The research that led to GLP-1 drugs began with a peptide isolated from Gila monster venom in 1992, but Ozempic's active ingredient, semaglutide, is a synthetic analog of human GLP-1. It is not derived from animal venom. It is produced using genetically modified yeast cells.

How long does it take to manufacture Ozempic? A single batch of Ozempic takes 8 to 10 months from the start of yeast fermentation to finished product release. This includes fermentation, purification, chemical modification, formulation, fill-finish, and quality testing.

What is compounded semaglutide made from? Compounded semaglutide is made from the same peptide as brand-name Ozempic, but the peptide is purchased from specialized manufacturers and prepared by state-licensed compounding pharmacies. The active ingredient is identical, but the manufacturing process and regulatory oversight differ.

Is compounded semaglutide the same as Ozempic? The active peptide is the same, but compounded semaglutide is not FDA-approved and is not manufactured under the same quality standards as Ozempic. Compounded versions may have different inactive ingredients, concentrations, and storage requirements. They are not interchangeable with brand-name products.

Why is there an Ozempic shortage? The shortage from 2022 to 2024 was caused by demand exceeding Novo Nordisk's manufacturing capacity. The company has since expanded production facilities in Denmark, France, and North Carolina. As of April 2026, semaglutide supply has stabilized, but intermittent shortages still occur.

Where does FormBlends get semaglutide? FormBlends partners with state-licensed 503A compounding pharmacies that source semaglutide API from FDA-registered U.S. manufacturers or ISO-certified European manufacturers. Each batch undergoes third-party HPLC testing to verify purity and potency before compounding.

Can I trust compounded semaglutide? Compounded semaglutide from a reputable 503A pharmacy that performs batch testing and discloses API sources is generally safe and effective. However, it has not undergone FDA review. Patients should verify the pharmacy's license, API source, and testing practices before accepting a prescription.

How do I know if my semaglutide is real? For brand-name Ozempic, check the pen for Novo Nordisk branding, a lot number, and an expiration date. The solution should be clear and colorless. For compounded semaglutide, ask the pharmacy for the certificate of analysis and verify the lot number matches the vial label. If the pharmacy cannot provide documentation, do not use the product.

Is semaglutide made in China? Some compounding pharmacies source semaglutide API from Chinese manufacturers. Novo Nordisk does not manufacture Ozempic in China. FormBlends partner pharmacies do not use Chinese-sourced API unless it undergoes third-party testing in the U.S. and meets the same purity standards as U.S. or European sources.

What inactive ingredients are in Ozempic? Ozempic contains disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. These ingredients stabilize the semaglutide and prevent bacterial growth in the multi-dose pen. Compounded semaglutide typically uses bacteriostatic water, sodium phosphate, and benzyl alcohol as preservatives.

Why does Ozempic cost so much if it's made from yeast? The cost reflects the 8-to-10-month manufacturing timeline, extensive quality testing, clinical trial expenses (over $1 billion for the STEP and SUSTAIN programs), and patent protection. Novo Nordisk's semaglutide patents expire in 2031-2033, after which generic versions will become available at lower cost.

Sources

1. Eng J et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry. 1992.
2. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
3. Novo Nordisk. Annual Report 2023. Corporate financial and manufacturing disclosures. 2024.
4. FDA Drug Shortages Database. Semaglutide injection shortage status. Accessed April 2026.
5. FDA. Statement on compounded semaglutide during drug shortages. June 2023.
6. Novo Nordisk Quality Review. Internal batch success rates and quality metrics. 2022.
7. FDA Inspection Reports. Novo Nordisk Kalundborg facility. 2021.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
10. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6 trial). New England Journal of Medicine. 2016.
11. American College of Gastroenterology. Guidelines on GERD management. 2022.
12. USP Chapter 797. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2023.
13. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy compounding. U.S. Code Title 21.
14. European Medicines Agency. ISO 13485 certification standards for medical device and pharmaceutical manufacturing. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.